Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AZD5851 |
Synonyms | |
Therapy Description |
AZD5851 comprises T-cells engineered to express a chimeric antigen receptor (CAR) targeting GPC3 and a dominant negative TGF-beta type II receptor, which may inhibit tumor growth (J Immunol (2023) 210 (1_Supplement): 68.17) |